Stockreport

Lung Transplant Rejection Research Report 2025-2035: TFF Pharmaceuticals and Astellas Lead by Investing Heavily in R&D to Improve Existing Immunosuppressive Therapies, and Develop New Biol...

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF attacking transplanted tissue, potentially leading to graft failure. This can occur in three main phases: hyperacute, acute, and chronic rejection. Causes include mismat [Read more]